Anti-Estrogen Receptor-alpha 36 Antibody, Non-Fucosylated (BioBet-844ZP) (CAT#: BioBet-844ZP) Datasheet

ESR1

estrogen receptor 1

ER-alpha36 is a novel variant of ER-alpha, is expressed in ER-positive and-negative human breast carcinomas.

ESR1; estrogen receptor 1

Nucleus, Golgi apparatus, Plasma membrane

Diseases associated with ESR1 include Estrogen Resistance and Breast Cancer.

Its related pathways are Estrogen signaling pathway and Signaling by GPCR.

Nuclear hormone receptor. Steroid hormones and their receptors participate in the regulation of eukaryotic gene expression and affect cell proliferation and differentiation in target tissues. Ligand-dependent nuclear deactivation includes direct homodimer binding to palindromic estrogen response element (ERE) sequences, or binding to other DNA transcription factors, such as AP-1/c-Jun, c-Fos, ATF-2, Sp1 and Sp3, to mediate ERE independent signal transduction. Ligand binding initiates a conformational change, allowing subsequent binding or combined binding to the multiprotein co-activator complex through the LXXLL motif of the respective components. Cross-inhibition occurs in a cell type-specific way between the estrogen receptor (ER) and nf-kpa-b. Reduce nf-kpa-b dna binding activity, inhibit nf-kpa-b-mediated transcription from IL6 promoter, and replace RELA/p65 from the promoter and related co-regulators. Recruited to the nf-kpa-b response elements of CCL2 and IL8 promoters, it can replace CREBBP. There are nf-kpa-b components RELA/p65 and NFKB1/p50 in the ERE sequence. It can also cooperate with nf-kpa-b to activate transcription related to recruiting neighboring response elements; this function involves CREBBP. Can activate the transcriptional activity of TFF1. It also mediates membrane-activated estrogen signals, involving various kinase cascades. Isoform 3 is involved in the activation of NOS3 and the production of endothelial nitric oxide. Isoforms lacking one or several functional domains are believed to regulate transcriptional activity through competitive ligand or DNA binding and/or heterodimerization with the full-length receptor. It is essential for the transcriptional regulation of BRCA1 and BCAS3 mediated by mta1. Isoform 3 can bind to ERE and inhibit Isoform 1.

Cancer antibody; Gene Regulation antibody; Neuroscience antibody; Signaling Transduction antibody

Phosphorylated by cyclin A/CDK2 and CK1. Phosphorylation probably enhances transcriptional activity. Self-association induces phosphorylation. Dephosphorylation at Ser-118 by PPP5C inhibits its transactivation activity. Phosphorylated by LMTK3 in vitro. Glycosylated; contains N-acetylglucosamine, probably O-linked. Ubiquitinated; regulated by LATS1 via DCAF1 it leads to ESR1 proteasomal degradation (PubMed:21602804, PubMed:28068668). Deubiquitinated by OTUB1 (PubMed:19383985). Dimethylated by PRMT1 at Arg-260. The methylation may favor cytoplasmic localization. Palmitoylated (isoform 3). Not biotinylated (isoform 3). Palmitoylated by ZDHHC7 and ZDHHC21. Palmitoylation is required for plasma membrane targeting and for rapid intracellular signaling via ERK and AKT kinases and cAMP generation, but not for signaling mediated by the nuclear hormone receptor.

Protein Based Therapies
Monoclonal antibody (mAb)

IgG

BioBet-844ZP

Mouse

Human

This is an antibody binds to ER-α36, ER-α36 positively regulates HER2 expression and the population of ALDH1 positive breast cancer cells, and suggested that non-genomic estrogen signaling mediated by ER-α36 is involved in maintenance and regulation of breast cancer stem cells.

Cancer

Cancer